Enveric's Q3 FY2020 shows revenue down 7.3% YoY to $8.5M, but net loss improved 25.2% to -$1.6M, partly due to a weak prior-year comparison. The company has $740K in long-term debt, no cash or equity data reported, and 7 dilution events in the past 12 months, with a recent prospectus for up to $2.4M offering. Note this quarter is nearly 6 years old, so data may be stale.
•Revenue declined 7.3% YoY to $8.5M from $9.1M, indicating slight shrinkage.
•Net loss improved to -$1.6M from -$2.2M (25.2% improvement), but EPS swung from -$14.58 to -$1.08 largely due to a massive share count increase (dilution).
•Balance sheet is opaque: no cash or equity reported; long-term debt stands at $740K.
•High dilution risk: 7 dilution events in 12 months and a recent $2.4M offering (424B5 filed June 2026) signal ongoing capital raises.
Informational summary based on SEC XBRL figures · generated by AI agent. Not investment advice.
A clinical-stage biotech developing novel psychedelic- and cannabinoid-inspired neurological medicines, with a pipeline aimed at anxiety, depression, and cancer-related psychological distress.
🧠 Next-generation psychedelic compounds designed for improved precision versus first-generation psilocybin or MDMA
🔬 EV-103 and related pipeline assets target mental health conditions with the highest unmet medical need
⚠️ Pre-revenue clinical stage — high risk and high potential, with outcomes entirely dependent on trial results
Enveric Biosciences is a clinical-stage biotechnology company focused on developing novel psychedelic- and cannabinoid-inspired medicines for neurological and mental health conditions. Its pipeline targets anxiety, depression, and cancer-related psychological distress. The company is known for its next-generation psychedelic compounds, such as EV-103, which are designed to offer improved precision compared to first-generation treatments like psilocybin or MDMA. Enveric operates in the cannabis-related pharmaceutical and biotech sector, leveraging cannabinoid-inspired molecules alongside psychedelic compounds. As a pre-revenue clinical-stage company, its value depends entirely on the outcomes of ongoing and future clinical trials.
What is Enveric Biosciences' business model?
Enveric Biosciences operates as a clinical-stage pharmaceutical and biotech company, meaning it has no approved products or current revenues. Its business model is centered on research and development of novel drug candidates, with the goal of advancing them through clinical trials and eventually obtaining regulatory approval for commercialization. The company's pipeline includes EV-103 and related assets targeting mental health conditions with high unmet medical need. As a pre-revenue entity, Enveric relies on funding from investors, partnerships, and grants to support its R&D activities. Success depends on positive trial results, regulatory milestones, and potential licensing or collaboration deals with larger pharmaceutical firms.
What category does Enveric Biosciences (ENVB) fall under in the cannabis sector?
Enveric Biosciences is classified as a cannabis-related pharmaceutical and biotech company on WeedMarketCap. This category includes companies that develop drugs or therapies inspired by or derived from cannabinoids, even if they do not directly cultivate or sell cannabis. Enveric's focus on cannabinoid-inspired neurological medicines places it in the ancillary and pharmaceutical niche of the cannabis sector, distinct from plant-touching operators like MSOs or Canadian LPs. As a clinical-stage biotech, it is considered high-risk and high-potential, with its value tied to scientific innovation and trial outcomes rather than current product sales or cultivation capacity.
What are the key differentiators of Enveric Biosciences (ENVB)?
Enveric Biosciences differentiates itself through its focus on next-generation psychedelic and cannabinoid-inspired compounds designed for improved precision over first-generation treatments like psilocybin or MDMA. Its lead pipeline asset, EV-103, targets mental health conditions with the highest unmet medical need, including anxiety, depression, and cancer-related psychological distress. The company's approach emphasizes novel molecular design to potentially enhance efficacy and reduce side effects. However, as a pre-revenue clinical-stage company, Enveric carries high risk, with outcomes entirely dependent on clinical trial results. This combination of innovative science and early-stage development sets it apart from more established cannabis companies.
What should investors know about Enveric Biosciences' (ENVB) risk profile?
Enveric Biosciences is a pre-revenue clinical-stage biotech company, which inherently carries high risk. Its pipeline, including EV-103, has not yet been approved by regulators, and the company's future depends entirely on the success of clinical trials. Positive results could lead to significant upside, but negative outcomes could result in substantial losses. Enveric operates in the cannabis-related pharmaceutical space, which adds regulatory and market uncertainties. As of now, the company has no products, revenues, or profits, and it relies on external funding to sustain operations. Investors should be aware that this is a high-risk, high-potential opportunity, with outcomes tied to scientific and regulatory milestones rather than current financial performance.
